Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies

Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies Publisher Pubmed

Tajdini M ; Tavakoli K ; Jenkin SC ; Keykhaei M ; Hahn VS

Source: Journal of Cardiac Failure Published:2026

Abstract

Hypertrophic cardiomyopathy with left ventricular systolic dysfunction (HCM-LVSD) is a severe manifestation of HCM that is defined by a left ventricular ejection fraction <50%. LVSD is a risk factor for sudden cardiac death that warrants consideration of an implantable cardioverter-defibrillator. Pharmacological therapies are limited to guideline-directed medical therapy for heart failure with reduced ejection fraction, regardless of etiology. Patients with HCM-LVSD suffer from high morbidity and mortality rates, often requiring advanced heart failure therapies. Heart transplantation remains the definitive treatment for end-stage disease, but left ventricular assist devices (LVADs) can serve as bridges to transplantation in selected cases, despite unique anatomical challenges and higher complication rates. Future research must address the knowledge gaps in the prevention and treatment of HCM-LVSD, aiming to enhance quality of life, prevent the need for advanced heart failure therapies, and prolong survival. © 2026 The Authors.

Style	Citing Format
MLA	Tajdini M, et al.. "Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies." Journal of Cardiac Failure, vol. , no. , 2026, pp. -.
APA	Tajdini M, Tavakoli K, Jenkin SC, Keykhaei M, Hahn VS (2026). Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies. Journal of Cardiac Failure, (), -.
Chicago	Tajdini M, Tavakoli K, Jenkin SC, Keykhaei M, Hahn VS. "Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies." Journal of Cardiac Failure , no. (2026): -.
Harvard	Tajdini M et al. (2026) 'Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies', Journal of Cardiac Failure, (), pp. -.
Vancouver	Tajdini M, Tavakoli K, Jenkin SC, Keykhaei M, Hahn VS. Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies. Journal of Cardiac Failure. 2026;():-.
BibTex	@article{ author = {Tajdini M and Tavakoli K and Jenkin SC and Keykhaei M and Hahn VS}, title = {Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies}, journal = {Journal of Cardiac Failure}, volume = {}, number = {}, pages = {-}, year = {2026} }
RIS	TY - JOUR AU - Tajdini M AU - Tavakoli K AU - Jenkin SC AU - Keykhaei M AU - Hahn VS TI - Hypertrophic Cardiomyopathy With Left Ventricular Systolic Dysfunction: Integrating Pharmacological, Device, and Advanced Heart Failure Therapies JO - Journal of Cardiac Failure VL - IS - SP - EP - PY - 2026 ER -

Science Communicator Platform

Authors

Abstract